Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Veracyte, Inc. (VCYT)

50.31 +0.03 (+0.06%)
At close: October 28 at 4:00:00 PM EDT
50.70 +0.39 (+0.78%)
Pre-Market: 7:38:06 AM EDT
Trade VCYT on Coinbase
Chart Range Bar
Loading chart for VCYT
  • Previous Close 50.28
  • Open 50.00
  • Bid 33.30 x 200
  • Ask 59.52 x 200
  • Day's Range 49.87 - 51.79
  • 52 Week Range 29.45 - 60.91
  • Volume 1,397,992
  • Avg. Volume 1,395,765
  • Market Cap (intraday) 4.044B
  • Beta (5Y Monthly) 1.95
  • PE Ratio (TTM) 35.94
  • EPS (TTM) 1.40
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 59.73
  • Zacks Rating Neutral

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

www.veracyte.com

755

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VCYT
19.50%
S&P 500 (^GSPC)
13.13%

1-Year Return

VCYT
41.32%
S&P 500 (^GSPC)
12.38%

3-Year Return

VCYT
155.12%
S&P 500 (^GSPC)
88.08%

5-Year Return

VCYT
2.15%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 150.32M
Earnings 25.49M
Profit Margin 16.96%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
50M
100M
150M
15.0%
20.0%
25.0%

Analyst Insights

View More

Analyst Price Targets

45.00 Low
59.73 Average
50.31 Current
70.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/15/2026
Analyst Freedom Capital Markets
Rating Action Maintains
Rating Buy
Price Action Maintains
Price Target 66 -> 66

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.37%

  • Return on Assets (ttm)

    4.09%

  • Return on Equity (ttm)

    8.77%

  • Revenue (ttm)

    561.9M

  • Net Income Avi to Common (ttm)

    114.48M

  • Diluted EPS (ttm)

    1.40

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    485.23M

  • Total Debt/Equity (mrq)

    2.89%

  • Levered Free Cash Flow (ttm)

    106.23M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: